Matrifen (Fentanyl)

Fentanyl in Matrifen binds to mu‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that diminish the perception of pain. The patch releases the drug slowly through the skin, maintaining consistent plasma levels for prolonged pain relief.

The prescribed dose of Matrifen is determined by the treating clinician based on the patient’s pain severity, opioid tolerance, and clinical response. Dosage adjustments are made according to individual needs and safety considerations.

Safety of fentanyl patches in pregnancy or lactation has not been established. They are generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To order Matrifen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Matrifen delivers fentanyl via a transdermal system, offering continuous drug exposure without daily oral dosing. Compared with immediate‑release oral opioids, it provides more stable plasma concentrations, fewer peaks and troughs, and improved convenience for patients needing long‑term pain control.

Matrifen patches should be stored at room temperature, below 25 °C, in the original sealed pouch. Keep them away from direct sunlight, moisture and heat sources. Do not expose the patch to extreme temperatures or puncture the packaging.

The patch is applied to a clean, dry, hair‑free area of the upper torso or upper arm. Press firmly for about 30 seconds to ensure good adhesion, then cover with a protective dressing if needed. The patch remains in place for the prescribed duration, usually 72 hours, before being replaced.

The most serious risks include respiratory depression, severe hypotension, opioid dependence, and rare but severe skin reactions. Patients should be monitored closely for signs of breathing difficulty, excessive sedation, or allergic responses, and the patch should be removed immediately if serious adverse events occur.

Matrifen should not be used in patients who are opioid‑naïve, have uncontrolled severe respiratory disease, known hypersensitivity to fentanyl or patch components, or who are taking prohibited concomitant medications such as certain CNS depressants without medical supervision.